Bile duct cancer: New therapies & proven methods

Bile duct cancer is a relatively rare type of cancer. Two types are distinguished: intrahepatic cholangiocarcinoma (the cancer originates in the bile ducts within the liver) and extrahepatic cholangiocarcinoma (the cancer originates outside the liver). The intrahepatic form is classified as liver cancer. In Germany, approximately 8,200 people are diagnosed with bile duct and gallbladder cancer each year. In most cases, the tumor develops in the external bile ducts or in the gallbladder (extrahepatic). In about 3,000 of those affected, the cancer originates in the bile ducts within the liver (intrahepatic). Women are generally slightly more frequently affected than men. In Switzerland, only ≈463 people are diagnosed with the extrahepatic form annually (average rates 2018-2022)

Because bile duct cancer often causes no symptoms for a long time, it is usually discovered late. Therefore, the prognosis for those affected is often unfavorable. New diagnostic and therapeutic approaches can help to detect bile duct tumors earlier and thus improve the prognosis for patients. Learn which factors increase the risk of bile duct cancer, which symptoms occur, and which treatment methods are currently available.

A tumor in the bile ducts is also called Bile Duct Carcinoma, Cholangiocellular Carcinoma, or Cholangiocarcinoma. This belongs to the group of biliary carcinomas (BTC), that is, tumors that originate from the outermost tissue layer (epithelium) of the bile ducts and gallbladder.

Risk factors for the development of bile duct cancer include, among others:

Chronic inflammation of the bile ducts (cholangitis), e.g., due to shortened bile ducts or, rarely, primary sclerosing cholangitis (PSC)
Bile duct stones
Polyps on the lining of the gallbladder or cysts in the bile ducts
Being severely overweight (obesity)
Diabetes mellitus
Liver cirrhosis and fatty liver
(Especially chronic) infections such as hepatitis B, hepatitis C and HIV
Chronic inflammatory bowel diseases
Excessive alcohol consumption
Smoking
Age also plays a role, as most diagnoses are made after the age of 70. Other possible risk factors include, for example, contact with asbestos, ingestion of nitrosamines, or taking birth control pills.

Bile duct cancer initially causes no or hardly any symptoms. Even later, the symptoms are rather nonspecific. Many cancer diagnoses are incidental findings, for example, during gallbladder surgery. Due to the late onset and nonspecific symptoms, bile duct cancer is often only discovered in an advanced stage.

The following symptoms may indicate bile duct cancer:

Yellowish discoloration of the skin and eyeballs, similar to jaundice
Dark-colored urine
Light-colored stool
Extreme itching of the skin
Pain and pressure (mostly) in the upper abdomen
Enlargement of the gallbladder (palpable below the right rib cage)
Nausea and vomiting
Loss of appetite and general weakness

If bile duct cancer is suspected, the doctor will first clarify possible risk factors, pre-existing conditions, and any existing symptoms as part of the medical history.

Subsequently, some of the following examinations are usually carried out:

Physical examination (palpation of the right upper abdomen)
Blood tests (especially liver function tests, tumor markers)
Ultrasound examination (sonography) of the abdomen
Computer tomography (CT)
Magnetic resonance imaging (MRI) for detailed visualization of the bile ducts
X-ray examination to detect possible metastases in the lungs
Endoscopic retrograde cholangiopancreatography (ERCP)
Percutaneous transhepatic cholangiography (PTC)
Biopsy (tissue sampling), usually as part of the ERCP

The chances of successful treatment depend on the size, aggressiveness, and spread of the tumor(s). Cholangiocellular Carcinoma is considered particularly aggressive because it spreads early to other organs (e.g., the liver, pancreas, and intestines) and forms secondary tumors (metastases). Furthermore, bile duct cancer is often diagnosed only in an advanced stage. As a result, the prognosis for those affected is usually unfavorable: the relative 5-year survival rates are approximately 19% (women) and 23% (men). Therefore, it is all the more important to begin appropriate therapy as soon as possible after diagnosis.

The following treatment methods are available for bile duct cancer:

Surgery

If the tumor is detected at an early stage and can be completely removed, surgery is performed. This is the only treatment method with a prospect of a cure for bile duct cancer. During the operation, the tumor is removed. Depending on its location (within or outside the liver), parts of the liver and pancreas, as well as adjacent lymph nodes, are also removed. In the case of gallbladder cancer, the entire gallbladder is also removed.

Chemotherapy

Chemotherapy can be used to shrink a tumor before surgery or to destroy any remaining cancer cells after surgery. This increases the chance of complete tumor removal and reduces the risk of recurrence. Chemotherapy is also used when surgery is not possible, to slow tumor growth and potentially shrink the tumor.

Other treatment options

Radiation therapy: In some cases, the tumor can also be irradiated before surgery to shrink it.
Embolization in combination with chemotherapy or radiation: Tumor growth is slowed or stopped by delivering chemotherapeutic agents or a radioactive substance close to the cancer cells. At the same time, the artery that supplies the cancer cells locally is temporarily blocked (embolization).
Thermal ablation: In a minimally invasive procedure, cancer cells are destroyed using heat, thus temporarily preventing tumor growth.
Targeted therapy: Drugs with so-called kinase inhibitors block tumor growth by blocking important signaling pathways of the cancer cells.
Immunotherapy in combination with chemotherapy: An international study from Hannover Medical School (MHH) in 2023 shows that immunotherapy in combination with chemotherapy can improve treatment success in bile duct cancer with manageable side effects.
Bile drainage: The tumor may be blocking the bile duct. As a result, bile backs up and accumulates in the body. In this case, a stent is placed in the bile duct, or the bile is drained via a tube into the stomach, duodenum, or externally.
Palliative treatment: This involves treating accompanying symptoms when the cancer is advanced. Symptoms such as pain, digestive problems, and similar issues are alleviated to improve the patients' quality of life.

Some established cancer treatments are often associated with significant side effects. For bile duct cancer, emerging individualized treatment approaches offer new possibilities for patients. Personalized therapy makes it possible to target the individual cancer of each patient more specifically. The treatment is more closely tailored to the unique genetic, molecular, and cellular characteristics of the tumor. This aims to increase treatment success while simultaneously reducing unwanted side effects.

A blood test for cancer is not only an important step toward personalized treatment for bile duct cancer; it can also support diagnosis when cancer is suspected. By identifying the individual biological characteristics of the tumor, the test helps guide the selection of the most appropriate treatment and may increase the likelihood of early disease detection. The test can be performed at any stage of the disease.

After the blood sample is collected, it is sent to our specialists for detailed analysis to identify tumor-specific characteristics. The results are then promptly shared with the treating physician. Combined with additional diagnostic findings, these results help physicians determine the optimal combination of established and emerging treatment options for patients with bile duct cancer.

The following tests may be used to support diagnosis, identify tumor biomarkers, and personalize bile duct cancer therapy:

Oncotrace

establishes baseline values for CTC count, phenotype markers, and stemness markers in the bloodstream. These parameters provide a…

Show test

Oncocount

detects the presence of CTCs and quantifies their concentration in the bloodstream. A higher number of CTCs might…

Show test

Metastat

investigates the proteins that are related to the distant spread of cancer and the potential metastatic properties of…

Show test

Onconomics

provides highly detailed and accurate information about how effective specific anti-cancer drugs and targeted therapies are in treating…

Show test

Onconomics Plus

provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer…

Show test

Onconomics Extracts

is a unique and highly detailed test that provides information on how effective natural substances and plant…

Show test

Onconomics Extracts +

Onconomics Extracts+ provides highly detailed and accurate information about how effective specific natural substances and plant extracts are. Furthermore,…

Show test

ChemoSNiP

analyzes how each body reacts to a chemotherapy agent. It helps clinicians make superior decisions on which medication(s)…

Show test

Immune-Frame

provides insights into the current state of a patient’s immune system. It is used to guide treatment and…

Show test

ArrayCGH RGCC

helps identify chromosomal abnormalities and genetic disorders.

Show test

CAMBISeq

is used to predict cancer treatment response. The test analyzes 500+ genes, which are used as biomarkers to…

Show test

Onco-D-Clare

Early detection can make all the difference. Onco-D-Clare can help identify cancer risk even before symptoms appear.

Show test

InVyomma Plus

focuses on gut microbiome profiling, including analysis of short-chain fatty acids, and their association with cancer.

Show test

Our researchers at RGCC International work daily to address unmet medical needs and contribute to more precise individualized cancer diagnostics. We aim to support physicians and patients with our tests, enabling even more effective cancer treatments.

Are you interested in early cancer diagnosis, disease analysis, or therapy monitoring via a blood test? Then please get in touch! Our state-of-the-art tests are available exclusively to physicians within the RGCC network. Our methods can be used not only for bile duct cancer, but also for other types of cancer, such as bladder cancer, breast cancer, cervical and uterine cancer, colon cancer, prostate cancer, thyroid cancer, and lung cancer. Do you have any questions? Contact our highly specialized team at the help desk! We are happy to assist you.